Generic Name and Formulations:
Pyrazinamide 500mg; scored tabs.
Various generic manufacturers
Indications for Pyrazinamide:
Susceptible pulmonary tuberculosis.
Adults and Children:
15–30mg/kg once daily; max 2g daily. Or 50–70mg/kg twice weekly based on lean body weight.
Severe hepatic damage. Acute gout.
Use with other antituberculars. Monitor hepatic function and serum uric acid before and during therapy. Hepatocellular damage or hyperuricemia with acute gouty arthritis: discontinue. Patients at risk for hepatitis (eg, alcoholism). Diabetes (blood glucose may be harder to control). HIV: see literature. Pregnancy (Cat.C). Nursing mothers.
May interfere with Acetest or Ketostix.
Hepatitis, liver dysfunction, gout, GI disturbances, arthralgia, myalgia, blood dyscrasias (rare).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|